LianBio – NASDAQ:LIAN
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 1 hour
LianBio stock price monthly change
-92.10%
month
LianBio stock price quarterly change
-92.44%
quarter
LianBio stock price yearly change
-83.81%
year
LianBio key metrics
Market Cap | 34.47M |
Enterprise value | N/A |
P/E | -0.74 |
EV/Sales | N/A |
EV/EBITDA | 1.30 |
Price/Sales | N/A |
Price/Book | 0.16 |
PEG ratio | 0.15 |
EPS | -0.81 |
Revenue | N/A |
EBITDA | -105.91M |
Income | -87.98M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeLianBio stock price history
LianBio stock forecast
LianBio financial statements
| Dec 2022 | 0 | -18.27M | |
|---|---|---|---|
| Mar 2023 | 0 | -24.04M | |
| Jun 2023 | 0 | -21.62M | |
| Sep 2023 | 0 | -24.03M |
| 2027 | 264.12M | 52.88M | 20.02% |
|---|
Analysts Price target
Financials & Ratios estimates
| 2024-03-25 | -0.19 | -0.17 |
|---|
| Dec 2022 | 319960000 | 26.31M | 8.22% |
|---|---|---|---|
| Mar 2023 | 302583000 | 28.15M | 9.31% |
| Jun 2023 | 278798000 | 23.29M | 8.35% |
| Sep 2023 | 262902000 | 26.79M | 10.19% |
| Dec 2022 | -30.71M | 10.99M | 0 |
|---|---|---|---|
| Mar 2023 | -17.63M | 40.54M | 0 |
| Jun 2023 | -19.31M | 21.97M | 0 |
| Sep 2023 | -15.86M | 15.52M | 0 |
LianBio alternative data
| Aug 2023 | 163 |
|---|---|
| Sep 2023 | 163 |
| Oct 2023 | 163 |
| Nov 2023 | 163 |
| Dec 2023 | 163 |
| Jan 2024 | 163 |
| Feb 2024 | 163 |
| Mar 2024 | 163 |
| Apr 2024 | 163 |
| May 2024 | 163 |
| Jun 2024 | 163 |
| Jul 2024 | 163 |
LianBio other data
6.40%
-68.61%
of LIAN is owned by hedge funds
15
-24
6.90M
-74.36M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 1731 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | POUKALOV KONSTANTIN director | Ordinary Shares | 36,300 | $2.52 | $91,476 | ||
Option | POUKALOV KONSTANTIN director | Stock Option (Right to Buy) | 36,300 | $2.52 | $91,476 | ||
Option | PERCEPTIVE ADVISORS LLC director, 10 percent owner: | Ordinary Shares | 36,300 | $2.52 | $91,476 | ||
Option | PERCEPTIVE ADVISORS LLC director, 10 percent owner: | Stock Option (Right to Buy) | 36,300 | $2.52 | $91,476 | ||
Option | STONE ADAM LEO director, officer.. | Ordinary Shares | 36,300 | $2.52 | $91,476 | ||
Option | STONE ADAM LEO director, officer.. | Stock Option (Right to Buy) | 36,300 | $2.52 | $91,476 | ||
Option | GIANAKAKOS ANASTASIOS director | Ordinary Shares | 36,300 | $2.52 | $91,476 | ||
Option | GIANAKAKOS ANASTASIOS director | Stock Option (Right to Buy) | 36,300 | $2.52 | $91,476 | ||
Option | SILBERMANN SUSAN MICHELE director | Ordinary Shares | 36,300 | $2.52 | $91,476 | ||
Option | SILBERMANN SUSAN MICHELE director | Stock Option (Right to Buy) | 36,300 | $2.52 | $91,476 |
Week In Review: Tang Capital Offers $465M For LianBio Plus 80% Of Any Licenses/Divestments
Week In Review: Hansoh Sells Ex-China ADC Rights To GSK In $1.6 Billion Deal
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
Week In Review: Kelun-Biotech In $9.5 Billion ADC Deal With Merck
Week In Review: Jemicare Out-Licenses Prostate Cancer Therapy To Roche For $650 Million
LinkDoc Formally Withdraws Its U.S. IPO. Next Stop, Hong Kong?
LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market
-
When is LianBio's next earnings date?
Unfortunately, LianBio's (LIAN) next earnings date is currently unknown.
-
Does LianBio pay dividends?
Yes, LianBio pays dividends and its trailing 12-month yield is 2993.73% with 0% payout ratio. The last LianBio stock dividend of undefined was paid on 5 Sep 2025.
-
How much money does LianBio make?
LianBio has a market capitalization of 34.47M. LianBio made a loss 110.29M US dollars in net income (profit) last year or -$0.17 on an earnings per share basis.
-
What is LianBio's stock symbol?
LianBio is traded on the NASDAQ under the ticker symbol "LIAN".
-
What is LianBio's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of LianBio?
Shares of LianBio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does LianBio have?
As Jul 2024, LianBio employs 163 workers.
-
When LianBio went public?
LianBio is publicly traded company for more then 3 years since IPO on 1 Nov 2021.
-
What is LianBio's official website?
The official website for LianBio is lianbio.com.
-
Where are LianBio's headquarters?
LianBio is headquartered at 103 Carnegie Center Drive, Princeton, NJ.
-
How can i contact LianBio?
LianBio's mailing address is 103 Carnegie Center Drive, Princeton, NJ and company can be reached via phone at +60 9 486 2308.
LianBio company profile:
LianBio
lianbio.comExchange:
NASDAQ
Full time employees:
163
Industry:
Biotechnology
Sector:
Healthcare
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
103 Carnegie Center Drive
Princeton, NJ 08540
Princeton, NJ 08540
CIK: 0001831283
ISIN: US53000N1081
CUSIP: 50202M102
